Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Corcept Therapeutics (CORT) Tops Q3 EPS by 4c, Revenues Miss; Narrows FY20 Revenue Guidance Below Consensus
November 3, 2020 4:13 PM ESTCorcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $86.33 million versus the consensus estimate of $90.87 million.
Financial Highlights
Revenue of $86.3 million, a 6 percent increase from third quarter 2019GAAP diluted net income of $0.17 per share, compared to $0.22 per share in third quarter... More